Research progress of alectinib in the treatment of ALK-positive non-small cell lung cancer / 中国肿瘤临床
Chinese Journal of Clinical Oncology
;
(24): 1173-1177, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-734112
ABSTRACT
Rizotinib is a first-generation anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) and plays an important role in the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC). However, as with other TKIs, resistance development can-not be avoided with crizotinib. This led to the development of second generation ALK-TKIs such as alectinib, ceritinib, and brigatinib. This article reviews the research progress on treatment of ALK-positive NSCLC with alectinib, which is one of the hotspots.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Clinical Oncology
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS